-transparent.png){kind=logo}
The effectiveness of chemoimmunotherapy was evaluated in 45 previously untreated stage III ovarian cancer patients. Response rate, progression-free interval, and survival were considerably better than in a similar group of 63 patients treated with a single alkylating agent alone.
Related Publications
W T Creasman, and
S A Gall, and
J A Blessing, and
H J Schmidt, and
S Abu-Ghazaleh, and
J K Whisnant, and
P J DiSaia
August 2007,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
W T Creasman, and
S A Gall, and
J A Blessing, and
H J Schmidt, and
S Abu-Ghazaleh, and
J K Whisnant, and
P J DiSaia
January 1989,
Gynecologic oncology,
W T Creasman, and
S A Gall, and
J A Blessing, and
H J Schmidt, and
S Abu-Ghazaleh, and
J K Whisnant, and
P J DiSaia
July 2013,
Gynecologic oncology,
W T Creasman, and
S A Gall, and
J A Blessing, and
H J Schmidt, and
S Abu-Ghazaleh, and
J K Whisnant, and
P J DiSaia
September 1985,
Cancer research,
W T Creasman, and
S A Gall, and
J A Blessing, and
H J Schmidt, and
S Abu-Ghazaleh, and
J K Whisnant, and
P J DiSaia
January 2006,
Gynecologic oncology,
W T Creasman, and
S A Gall, and
J A Blessing, and
H J Schmidt, and
S Abu-Ghazaleh, and
J K Whisnant, and
P J DiSaia
January 1996,
International journal of radiation oncology, biology, physics,
W T Creasman, and
S A Gall, and
J A Blessing, and
H J Schmidt, and
S Abu-Ghazaleh, and
J K Whisnant, and
P J DiSaia
July 2006,
Gynecologic oncology,
W T Creasman, and
S A Gall, and
J A Blessing, and
H J Schmidt, and
S Abu-Ghazaleh, and
J K Whisnant, and
P J DiSaia
January 1992,
American journal of obstetrics and gynecology,
W T Creasman, and
S A Gall, and
J A Blessing, and
H J Schmidt, and
S Abu-Ghazaleh, and
J K Whisnant, and
P J DiSaia
January 2018,
Journal of gynecologic oncology,
W T Creasman, and
S A Gall, and
J A Blessing, and
H J Schmidt, and
S Abu-Ghazaleh, and
J K Whisnant, and
P J DiSaia
May 2008,
Cancer,
